By Oncolytics Biotech, a leading biopharmaceutical company, presented groundbreaking data on pancreatic cancer treatment at the European Society for Medical Oncology (ESMO) meeting in Madrid. This significant development has caused shares of Oncolytics Biotech to soar on the Nasdaq.
Encouraging Progress in Phase 1/2 Study
The updated data from the Phase 1/2 study has shown remarkable results, providing hope for pancreatic cancer patients. Oncolytics Biotech reported a median progression-free survival of 7.2 months, surpassing historical outcomes by at least 25%. Furthermore, the interim median overall survival was an impressive 10.6 months. These findings demonstrate the efficacy of Oncolytics’ treatment approach.
Advancing Precision Promise Phase 3 Trial
Oncolytics Biotech’s President and CEO, Matt Coffey, expressed optimism about the future of their pancreatic cancer program. He highlighted that the data presented at the ESMO meeting serves as a solid foundation for their participation in the Precision Promise Phase 3 trial. This trial aims to further evaluate and validate the efficacy of Oncolytics’ treatment in pancreatic cancer patients.
Promising Safety Profile
In addition to its efficacy, Oncolytics’ treatment combination has demonstrated an excellent safety profile. Patients have tolerated the treatment well, with no safety concerns reported. This is a significant factor to consider when developing new treatment options for pancreatic cancer.
These recent developments indicate a promising future for pancreatic cancer patients and the advancement of medical oncology research. The innovative approach taken by Oncolytics Biotech offers new hope for those affected by this aggressive disease.
Contact info removed
Comments